Cargando…

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification

Estradiol is a major regulator of growth for the subset of breast cancers that express the estrogen receptor (ER, ESR1). Strategies to block ER action, via reduction of estradiol or direct inhibition of ER, have shown major success in the prevention and treatment of breast cancer. However, most ER-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kota, Karthik, Brufsky, Adam, Oesterreich, Steffi, Lee, Adrian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2017
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587405/ https://www.ncbi.nlm.nih.gov/pubmed/28924522 http://dx.doi.org/10.7759/cureus.1434

Ejemplares similares

Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
por: Steinman, Richard A, et al.
Publicado: (2012)

Precision Medicine in Hormone Receptor-Positive Breast Cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2018)

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole
por: Gyanchandani, Rekha, et al.
Publicado: (2016)

Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer
por: Puthanmadhom Narayanan, Susrutha, et al.
Publicado: (2023)

Estrogen-repressed genes – key mediators of estrogen action?
por: Zubairy, Simeen, et al.
Publicado: (2005)

To bind or not to bind - FoxA1 determines estrogen receptor action in breast cancer progression
por: Watters, Rebecca J, et al.
Publicado: (2012)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
por: Kumeta, Toko, et al.
Publicado: (2019)

WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines
por: Sikora, Matthew J., et al.
Publicado: (2016)

Lysine in Combination With Estradiol Promote Dissemination of Estrogen Receptor Positive Breast Cancer via Upregulation of U2AF1 and RPN2 Proteins
por: Vazquez Rodriguez, Gabriela, et al.
Publicado: (2020)

An immune-humanized patient-derived xenograft model of estrogen-independent, hormone receptor positive metastatic breast cancer
por: Scherer, Sandra D., et al.
Publicado: (2021)

EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer
por: Li, Zheqi, et al.
Publicado: (2023)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

Targeted mutation detection in breast cancer using MammaSeq™
por: Smith, Nicholas G., et al.
Publicado: (2019)

Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor–Positive Breast Cancer
por: Carleton, Neil, et al.
Publicado: (2021)

Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk
por: Dall, Genevieve Victoria, et al.
Publicado: (2017)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
por: Brufsky, Adam, et al.
Publicado: (2022)

Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
por: Rangel, Nelson, et al.
Publicado: (2017)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
por: Brufsky, Adam, et al.
Publicado: (2023)

Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen Receptor-Positive Breast Cancer
por: Ding, Jingxian, et al.
Publicado: (2022)

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer
por: Schroeder, Brock, et al.
Publicado: (2017)

Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects
por: Liao, Hao, et al.
Publicado: (2020)

Non-coding single nucleotide variants affecting estrogen receptor binding and activity
por: Bahreini, Amir, et al.
Publicado: (2016)

An amphioxus orthologue of the estrogen receptor that does not bind estradiol: Insights into estrogen receptor evolution
por: Paris, Mathilde, et al.
Publicado: (2008)

Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2022)

3D Model of Lamprey Estrogen Receptor with Estradiol and 15α-Hydroxy-Estradiol
por: Baker, Michael E., et al.
Publicado: (2009)

Effects of 17β-Estradiol and Estrogen Receptor Antagonists on the Proliferation of Gastric Cancer Cell Lines
por: Kim, Myung-Jin, et al.
Publicado: (2013)

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways
por: Lundholt, BK, et al.
Publicado: (2000)

Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer
por: Liu, Jian, et al.
Publicado: (2021)

Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status
por: Pais, Adi, et al.
Publicado: (2016)

Knockdown of LMTK3 in the Endometrioid Adenocarcinoma Cell Line Ishikawa: Inhibition of Growth and Estrogen Receptor α
por: Cai, Guiyang, et al.
Publicado: (2021)

Estradiol accelerates liver regeneration through estrogen receptor α
por: Tsugawa, Yoji, et al.
Publicado: (2019)

Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer
por: Al Mahmasani, Layal, et al.
Publicado: (2023)

Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
por: Kota, Karthik, et al.
Publicado: (2017)

Estrogen Receptors and Their Implications in Colorectal Carcinogenesis
por: Caiazza, Francesco, et al.
Publicado: (2015)

Interplay between estrogen receptor and AKT in Estradiol-induced alternative splicing
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications
por: Di Zazzo, Erika, et al.
Publicado: (2018)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)

Semi-deconvolution of bulk and single-cell RNA-seq data with application to metastatic progression in breast cancer
por: Lei, Haoyun, et al.
Publicado: (2022)

Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0kulheollebehumgg96vp5ua4v